FTC Order Blocks Fresenius’ Ability To Inflate Medicare Venofer
Executive SummaryThe Federal Trade Commission is offering to set aside concerns with a Venofer licensing deal between Fresenius and Daiichi Sankyo if Fresenius continues to report a product price to Medicare that is no higher than the current market price
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.